You are here

Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2018

OXFORD, United Kingdom and CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT) will announce its financial results for the first quarter ended 30 April 2018 on 5 June 2018.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is currently conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

   
Summit  
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson  
   
N+1 Singer (Joint Broker)Tel:+44 (0)20 7496 3000
Aubrey Powell / Jen Boorer  
   
Panmure Gordon (Joint Broker)Tel:+44 (0)20 7886 2500
Freddy Crossley  
   
MacDougall Biomedical Communications (US)Tel:+1 781 235 3060
Karen Sharma ksharma@macbiocom.com
   
Consilium Strategic Communications (UK)Tel:+44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson / summit@consilium-comms.com
Lindsey Neville  
   

-END-

Friday, June 1, 2018 - 07:00